257 related articles for article (PubMed ID: 25090288)
21. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.
Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U
Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496
[TBL] [Abstract][Full Text] [Related]
22. Stereotactic ablative radiotherapy for primary renal cell carcinoma.
Yang DX; Kwon YS; Timmerman R; Hannan R
Clin Transl Radiat Oncol; 2024 Jan; 44():100705. PubMed ID: 38073715
[TBL] [Abstract][Full Text] [Related]
23. A review of stereotactic ablative radiotherapy for nonmetastatic renal cell carcinoma.
Zalay O; Mehra P; Pereira I; Malone J; Malone S
World J Urol; 2024 Jan; 42(1):52. PubMed ID: 38244135
[TBL] [Abstract][Full Text] [Related]
24. Extracranial oligometastatic renal cell carcinoma: current management and future directions.
Loh J; Davis ID; Martin JM; Siva S
Future Oncol; 2014 Apr; 10(5):761-74. PubMed ID: 24799057
[TBL] [Abstract][Full Text] [Related]
25. Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer.
Doyle E; Killean AJ; Harrow S; Phillips ID
Radiother Oncol; 2024 Jul; 196():110288. PubMed ID: 38648995
[TBL] [Abstract][Full Text] [Related]
26. Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer.
Zafra J; Onieva JL; Oliver J; Garrido-Barros M; González-Hernández A; Martínez-Gálvez B; Román A; Ordóñez-Marmolejo R; Pérez-Ruiz E; Benítez JC; Mesas A; Vera A; Chicas-Sett R; Rueda-Domínguez A; Barragán I
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674117
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
[TBL] [Abstract][Full Text] [Related]
28. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney).
Siva S; Ali M; Correa RJM; Muacevic A; Ponsky L; Ellis RJ; Lo SS; Onishi H; Swaminath A; McLaughlin M; Morgan SC; Cury FL; Teh BS; Mahadevan A; Kaplan ID; Chu W; Grubb W; Hannan R; Staehler M; Warner A; Louie AV
Lancet Oncol; 2022 Dec; 23(12):1508-1516. PubMed ID: 36400098
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer.
Iyengar P; Westover K; Timmerman RD
Semin Respir Crit Care Med; 2013 Dec; 34(6):845-54. PubMed ID: 24258574
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic radiotherapy in oligometastatic cancer.
Kennedy TAC; Corkum MT; Louie AV
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
[TBL] [Abstract][Full Text] [Related]
31. New concepts and insights into the role of radiation therapy in extracranial metastatic disease.
Ricardi U; Filippi AR; Franco P
Expert Rev Anticancer Ther; 2013 Oct; 13(10):1145-55. PubMed ID: 24134418
[TBL] [Abstract][Full Text] [Related]
32. Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review.
Gouveia AG; Chan DCW; Hoskin PJ; Marta GN; Trippa F; Maranzano E; Chow E; Silva MF
Radiother Oncol; 2021 Oct; 163():55-67. PubMed ID: 34333087
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review.
Kothari G; Foroudi F; Gill S; Corcoran NM; Siva S
Acta Oncol; 2015 Feb; 54(2):148-57. PubMed ID: 25140860
[TBL] [Abstract][Full Text] [Related]
34. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma.
Svedman C; Sandström P; Pisa P; Blomgren H; Lax I; Kälkner KM; Nilsson S; Wersäll P
Acta Oncol; 2006; 45(7):870-5. PubMed ID: 16982552
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma in Non-surgical Candidates: Initial Clinical Experience.
Chang JH; Cheung P; Erler D; Sonier M; Korol R; Chu W
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e109-14. PubMed ID: 27131756
[TBL] [Abstract][Full Text] [Related]
36. Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer.
Ali M; Koo K; Chang D; Chan P; Oon SF; Moon D; Murphy DG; Eapen R; Goad J; Lawrentschuk N; Azad AA; Chander S; Shaw M; Hardcastle N; Siva S
Radiat Oncol; 2024 Feb; 19(1):23. PubMed ID: 38355495
[TBL] [Abstract][Full Text] [Related]
37. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II.
Siva S; Chesson B; Bressel M; Pryor D; Higgs B; Reynolds HM; Hardcastle N; Montgomery R; Vanneste B; Khoo V; Ruben J; Lau E; Hofman MS; De Abreu Lourenco R; Sridharan S; Brook NR; Martin J; Lawrentschuk N; Kron T; Foroudi F
BMC Cancer; 2018 Oct; 18(1):1030. PubMed ID: 30352550
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
[TBL] [Abstract][Full Text] [Related]
39. Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5.
Olson R; Liu M; Bergman A; Lam S; Hsu F; Mou B; Berrang T; Mestrovic A; Chng N; Hyde D; Matthews Q; Lund C; Glick D; Pai H; Basran P; Carolan H; Valev B; Lefresene S; Tyldesley S; Schellenberg D
BMC Cancer; 2018 Oct; 18(1):954. PubMed ID: 30286739
[TBL] [Abstract][Full Text] [Related]
40. Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy.
Blanchard M; Shim KG; Grams MP; Rajani K; Diaz RM; Furutani KM; Thompson J; Olivier KR; Park SS; Markovic SN; Pandha H; Melcher A; Harrington K; Zaidi S; Vile R
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):577-87. PubMed ID: 26461000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
